Brief: Windtree Therapeutics Announces Reduction In Arrythmias In New Study With Istaroxime, Pure SERCA2a Activator
02/01/2024 21:17
Jan 2 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE THERAPEUTICS ANNOUNCES REDUCTION IN ARRYTHMIAS IN
A NEW
STUDY WITH ISTAROXIME AND A PURE SERCA2A ACTIVATOR
Source text for Eikon: ID:nGNX5DSjK
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study